BioCentury | Jun 7, 2019
Company News

June 6 Company Quick Takes: Take two for Celgene's ozanimod; plus Protalix, ABPI, Axovant and Mylan

...1-phosphate receptor 5 Elizabeth S. Eaton and Mary Romeo, Staff Writers alpha galactosidase, pegunigalsidase alfa (PRX-102) AXO-AAV-OPMD (BB-301, papbarna) ozanimod...
BioCentury | Dec 14, 2018
Clinical News

Axovant discontinues development of nelotanserin after Phase II readout

...therapy from Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) (see "Axovant Gets Rights to Benitec's Gene Therapy BB-301"...
BioCentury | Jul 13, 2018
Company News

Axovant gets rights to Benitec's gene therapy BB-301

...gene therapy pipeline by obtaining exclusive, worldwide rights from Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) to BB-301...
...research collaboration to develop gene therapy products to treat neurological disorders. Under the deal for BB-301...
...Ltd. (NASDAQ:AXON), Basel, Switzerland Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC), North Sydney, Australia Business: Musculoskeletal Paul Bonanos BB-301, papbarna Axovant...
BioCentury | Jul 9, 2018
Company News

Axovant deepens gene therapy pipeline with Benitec deal

...gene therapy pipeline by obtaining exclusive, worldwide rights from Benitec Biopharma Ltd. (ASX:BLT; NASDAQ:BNTC) to BB-301...
...research collaboration to develop gene therapy products to treat neurological disorders. Under the deal for BB-301...
...$2.64 on the day. The partners announced the deal late Sunday in the U.S. Paul Bonanos BB-301, papbarna Axovant...
BioCentury | Apr 25, 2017
Distillery Therapeutics

Musculoskeletal

...the therapy into a single vector and planning for Phase I/IIa testing. Benitec has BB-301 (papbarna...
Items per page:
1 - 5 of 5